ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18165421.
- Also identified by DOI 10.1097/01.AOG.0000291582.24371.0f.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Postoperative intravenous (IV) chemotherapy for advanced stage ovarian cancer has been the standard treatment . Recent studies have found significant survival advantages with the use of adjuvant intraperitoneal (IP) chemotherapy. Combination IV/IP chemotherapy may be an option for well counseled, carefully selected patients with optimally debulked stage III ovarian cancer. However, IV/IP treatment also has increased rates of pain, fatigue, and hematologic, gastrointestinal , metabolic, and neurologic toxicities. Given the balance of efficacy, quality of life, and toxicity, the decision to use IP chemotherapy must be individualized.
Medical subject headings
- Antineoplastic Agents
- Infusions, Parenteral
- Neoplasms, Glandular and Epithelial
- Ovarian Neoplasms